Eastland's under the tongue, Bionomics disrupts further, Novogen adds on and Mesoblast's arthritic sheep.

The first patients have begun treatment in Bionomics' Phase 1 trial of its vascular disruption agent.

Genomics is old hat and proteomics is now where it's at, according to Richard Christopherson.

As it begins Phase IIa clinical trials, Mesoblast is riding high: its share price is climbing, its market capitalisation is booming and all that promise seems to be coming good.

Mesoblast announces strong interim results in fracture repair trial.

BioPharmica intends to offer an IPO on one of its spin-off companies, Cortical Dynamics.

The first two patients in Melbourne-based Mesoblast's (ASX:MSB) clinical trials have been implanted with adult stem cells.

Perth based BioPharmica (ASX:BPH) has opened a share purchase plan to raise AUD$2.5 million to fund the development of its portfolio of biomedical research.

The first few patients have been formally recruited for two pilot clinical trials of Melbourne-based Mesoblast's (ASX:MSB) adult stem cell platform technology.

Melbourne-based Mesoblast (ASX:MSB) has accelerated its clinical program for obtaining regulatory approvals for its adult stem cell platform technology following a successful pre-investigational new drug (IND) meeting with the US FDA.

Adult stem cell specialist Mesoblast (ASX:MSB) has received ethics approval to commence its first human orthopaedic trial.